Disclosures This article forms part of a supplement funded by Novo Nordisk. WES has received consulting fees (advisory boards) and grant support from: Roche, Novartis, Eli Lilly, Novo Nordisk, Schering-Plough, Takeda, AstraZeneca, Eisai, Merck Sharpe & Dohme, Falk Foundation, Bristol-Meyers Squibb and Berlin Chemie.
Early clinical studies with liraglutide
Article first published online: 23 SEP 2010
© 2010 Blackwell Publishing Ltd
International Journal of Clinical Practice
Special Issue: Liraglutide in Type 2 Diabetes: From Design to Clinical Practice
Volume 64, Issue Supplement s167, pages 12–20, October 2010
How to Cite
Schmidt, W. E. (2010), Early clinical studies with liraglutide. International Journal of Clinical Practice, 64: 12–20. doi: 10.1111/j.1742-1241.2010.02500.x
- Issue published online: 23 SEP 2010
- Article first published online: 23 SEP 2010
- Paper received July 2010, accepted July 2010
- 2National Institute for Health and Clinical Excellence. Type 2 diabetes. The management of type 2 diabetes (update). London: Royal College of Physicians, 2008. Available from: http://www.nice.org.uk/nicemedia/pdf/CG66NICEGuideline.pdf (accessed 19 August 2010).
- 9No impairment of hypoglycemia counterregulation via glucagon with NN2211, a GLP-1 derivative, in subjects with type 2-diabetes. Diabetes 2003; 52(Suppl. 1): A128., , , , .
- 11One week’s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and α- and β-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004; 53: 1187–94., , et al.
- 18Near normalisation of blood glucose improves the potentiating effect of GLP-1 on glucose-induced insulin secretion in patients with type 2 diabetes. 2008; 51: 632–40., , et al.
- 19Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993; 214: 829–35., , .
- 22Metabolism and excretion of the once-daily human GLP-1 analogue liraglutide in healthy subject and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Diabetologia 2008; 51(Suppl. 1): S356., , et al.
- 26Influence of hepatic impairment on pharmacokinetics of the long-acting human GLP-1 analogue liraglutide. Diabetes 2007; 56(Suppl. 1): A145., , et al.
- 28A randomised, double-blind, cross-over trial investigating the effect of liraglutide on the absorption pharmacokinetics of concomitantly administered oral drugs in healthy subjects. Diabetes 2008; 57(Suppl.1): A130., , , , , .
- 29The effect of liraglutide on the absorption pharmacokinetics of concomitant oral drugs with different solubility and permeability properties in healthy subjects. Diabetologia 2008; 51(Suppl. 1): S355., , , , , .
- 33The once-daily human GLP-1 analogue liraglutide improves both absolute and baseline corrected postprandial glucose levels. Diabetes 2008; 57(Suppl. 1): P556., , , .
- 36NN2211-1310 International Study Group. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care 2004; 27: 1335–42., , , , ;
- 40Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. Diabet Med 2008; 25: 152–6., , et al.
- 43Liraglutide induces beta cell proliferation and protects from interleukin-1-beta induced beta cell apoptosis in human islets. Diabetologia 2008; 51(Suppl. 1): S212–3., , , , .
- 44Effects of the once-daily human GLP-1 analogue liraglutide on appetite and energy intake in type 2 diabetes. Diabetologia 2008; 51(Suppl. 1): S355., , et al.
- 46on behalf of the LEAD-1 SU study group. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009; 26: 268–78., , et al.;
- 48on behalf of the LEAD-5 (Liraglutide Effect and Action in Diabetes 5) met+SU Study Group. Liraglutide vs insulin glargine and placebo in combination with metformin and sulphonylurea therapy in type 2 diabetes mellitus: a randomised controlled trial (LEAD-5 met+SU). Diabetologia 2009; 52: 2046–55., , et al.;